TScan is dedicated to creating life-changing T cell therapies for patients by unleashing the untapped potential of the human immune system. TScan Therapeutics was founded in 2018 by a small group of scientists led by Dr. Stephen Elledge (Harvard Medical School/HHMI). TScan is discovering and developing novel TCR-engineered T cell therapies for the treatment of cancer. Our discovery platform is centered around a breakthrough technology that enables the rapid, comprehensive, and genome-wide identification of the peptide antigen targets of T cell receptors. This technology greatly enhances our ability to understand the specific antigens that drive important disease processes, including tumor cell recognition by the immune system, self-reactivity in autoimmune disorders, and acquired immunity in infectious disease. TScan is using the platform in oncology to discover new TCR/target pairs and to rapidly move novel TCRs into clinical development.
Location: United States, Massachusetts, Waltham
Employees: 51-200
Total raised: $183M
Founded date: 2018
Investors 4
| Date | Name | Website |
| - | K2 HealthV... | k2healthve... |
| - | 6 Dimensio... | 6dimension... |
| - | RA Capital... | racap.com |
| - | GV | gv.com |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 25.01.2021 | Series C | $100M | - |
| 09.01.2020 | Series B | $35M | - |
| 24.07.2019 | Series B | $48M | - |
Mentions in press and media 11
| Date | Title | Description |
| 16.06.2026 | Cellares Secures $327M, Revolutionizing Cell Therapy Manufacturing Globally | Cellares closed its Series D funding at $327 million, backed by ARK Invest, Prime Radiant Partners, and other major investors. This capital drives global expansion of its automated cell therapy manufacturing. The IDMO model and Smart Factor... |
| 15.06.2026 | Cellares Expands Series D To $327 Million With $50 Million Investment From Prime Radiant Partners | Cellares announced that Prime Radiant Partners has invested $50 million in the company’s Series D financing, bringing the total round to $327 million and providing additional capital to support commercial operations, a planned initial publi... |
| 12.11.2024 | TScan Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update | Upcoming oral presentation for the ALLOHATM Phase 1 heme trial at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition Company to host virtual KOL event featuring Ran Reshef, M.D., M.Sc., on Tuesday, December 10th at ... |
| 06.03.2024 | TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update | - |
| 05.01.2023 | TScan Therapeutics Announces 2023 Clinical Plans and Highlights Recent Progress | Phase 1 umbrella trial of TSC-100 and TSC-101 active in five sites; on track to enroll first two cohorts in 1H 2023 with interim data by end of 2023 Advancing solid tumor program with development of several TCRs for multiple HLAs across mul... |
| 13.12.2021 | TScan Therapeutics Announces Poster Presentations at the 63rd American Society of Hematology Annual Meeting and Exposition | - Posters highlight discovery of TSC-101, manufacturing process and clinical development plan for liquid tumor candidates TSC-101 and TSC-102 - - Phase 1 clinical trial expected to initiate in the first half of 2021 - - Company to host virt... |
| 19.08.2021 | TScan Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Company Progress | Debuted as Publicly Traded Company and Raised $100 Million in Gross Proceeds to Fund Liquid and Solid Tumor Programs IND Submissions Expected in Fourth Quarter 2021 for Lead Liquid Tumor TCR-T Therapy Candidates, TSC-100 and TSC-101 WALTHAM... |
| 25.01.2021 | TScan Therapeutics Raises $100M in Series C Financing | TScan Therapeutics, a Waltham, Mass.-based biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies in oncology, closed a $100m Series C financing. Backers included new investors BlackRock, R... |
| 09.01.2020 | TScan Therapeutics Completes $35M Series B Funding | TScan Therapeutics, a Waltham, Mass.-based company dedicated to creating life-changing T cell therapies for patients, completed its $35m Series B funding. Backers included Novartis Institutes for BioMedical Research (NIBR), Pitango Venture ... |
| 24.07.2019 | TScan Therapeutics Raises Series B Financing; $48M To Date | TScan Therapeutics, a Boston, MA-based company that designs therapies that reprogram a patient’s own T cells to fight cancer, raised its Series B financing, with over $48m secured since inception. Backers included Bessemer Venture Partners,... |
Show more